Currently, breast cancer treatment is based on breast surgery, radiotherapy, and adjuvant endocrine therapy in hormone receptor-positive (HR+) patients and, where appropriate, (neo)adjuvant chemotherapy and HER2-targeted antibody treatment [3,4]. The gene discussed is ERBB2; the disease is breast cancer.